Weighing Antitumor Immunity against Life-threatening Myocarditis from Immune-Checkpoint Inhibitors

Weighing Antitumor Immunity against Life-threatening Myocarditis from Immune-Checkpoint Inhibitors

In this issue of Cancer Discovery, Salem and colleagues report a combination therapy for immune-checkpoint inhibitor (ICI) myocarditis using high-dose glucocorticoids, abatacept, and the JAK inhibitor ruxolitinib. The apparent efficacy of their strategy and an accompanying animal model provide furth...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer discovery 2023-05, Vol.13 (5), p.1040-1042
1. Verfasser: Dougan, Michael
Format: Artikel
Sprache:eng
Schlagworte:
Abatacept - therapeutic use
Humans
Immune Checkpoint Inhibitors - adverse effects
Myocarditis - chemically induced
Myocarditis - diagnosis
Myocarditis - drug therapy
Respiratory Muscles - pathology
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:In this issue of Cancer Discovery, Salem and colleagues report a combination therapy for immune-checkpoint inhibitor (ICI) myocarditis using high-dose glucocorticoids, abatacept, and the JAK inhibitor ruxolitinib. The apparent efficacy of their strategy and an accompanying animal model provide further evidence for common immune mechanisms underlying ICI toxicities. See related article by Salem et al., p. 1100 (2).
ISSN:2159-8274
2159-8290
DOI:10.1158/2159-8290.CD-23-0199